Recombinant Human CYLD

BRSS; CDMT; CYLD; CYLD1; CYLD1MFT; CYLDI; cylindromatosis (turban tumor syndrome); Deubiquitinating enzyme CYLD; EAC; EC 3.1.2.15; EC 3.4.19.12; FLJ20180; FLJ31664; KIAA0849FLJ78684; MFT1; probable ubiquitin carboxyl-terminal hydrolase CYLD; SBS; TEM; ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; ubiquitin thioesterase CYLD; Ubiquitin thiolesterase CYLD; Ubiquitin-specific-processing protease CYLD; USPL2

Product Name

Recombinant Human CYLD

Size

50μg, 200μg, 1mg

Species

Human

Host

E.Coli

Expression Region

1-226

Mol. Weight

46 KDa

Tags

N-terminal His-IF2DI Tag

Purity

Greater than 95% as determined by SDS-PAGE

Application

Western Blot, ELISA

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with 5% trehalose, pH7.4

Reconstitution

Centrifuge the vial prior to opening, reconstitute in sterile distilled water or buffer of interest to concentration of 0.1-1mg/ml by gently pipetting 2-3 times, don't vortex

Storage

The lyophilized protein is stable at -20°C for up to 1 year, the protein solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing 0.1% BSA (make sure BSA will NOT interfere with your experiment ) and store in working aliquots at -20°C to -80°C for 6 months.Avoid repeated freeze/thaw cycle.

Alternative Names

BRSS, CDMT, CYLD, CYLD1, CYLD1MFT, CYLDI, cylindromatosis (turban tumor syndrome), Deubiquitinating enzyme CYLD, EAC, EC 3.1.2.15, EC 3.4.19.12, FLJ20180, FLJ31664, KIAA0849FLJ78684, MFT1, probable ubiquitin carboxyl-terminal hydrolase CYLD